

[APPENDIX 8-C FOR LICENSEES IN CHINA]

*FIRST AMENDMENT
TO
[AMENDED AND RESTATED] LICENSE AGREEMENT*

This FIRST AMENDMENT TO [AMENDED AND RESTATED] LICENSE AGREEMENT (this “**Amendment**”) is made as of _____ (the “**Amendment Effective Date**”) by and among **Gilead Sciences, Inc.**, a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, California 94404, USA (“**Gilead**”), the **Medicines Patent Pool**, a non-profit foundation registered under the laws of Switzerland, and having a principal place of business at Rue de Varembe 7, 1202 Geneva, Switzerland (“**MPP**”), and _____ a company registered under the laws of China, and having a registered office at _____, China (“**Licensee**”).

RECITALS

WHEREAS, Gilead, MPP, and Licensee entered into that certain [Amended and Restated] License Agreement effective as of _____ (the “**Agreement**”), pursuant to which MPP granted Licensee certain licenses with respect to Gilead’s proprietary pharmaceutical agents tenofovir alafenamide, tenofovir disoproxil fumarate, elvitegravir, and cobicistat for treatment of HIV and HBV in developing world countries; and

WHEREAS, Gilead, MPP, and Licensee wish to amend the Agreement to add certain licenses with respect to Gilead’s proprietary pharmaceutical agent bictegravir for treatment of HIV in developing world countries, in accordance with the terms and conditions of this Amendment, all as more fully described below.

NOW, THEREFORE, Gilead, MPP, and Licensee agree as follows:

1. Definitions.

- a. The definitions of the below terms are hereby deleted from Section 1 of the Agreement and replaced as follows:

“**Active Pharmaceutical Ingredient**” or “**API**” shall mean one or more of the following active pharmaceutical ingredients: tenofovir alafenamide (“**TAF**”), tenofovir disoproxil fumarate (“**TDF**”), elvitegravir (“**EVG**”), cobicistat (“**COBI**”), and bictegravir (“**BIC**”).

“**Combination Products**” shall mean COBI Combination Products, EVG Combination Products, TDF Combination Products, TAF Combination Products, BIC Combination Products, and Quad Products.

“**Patents**” shall mean (a) the patents and patent applications set forth in Appendix 2 hereto and (b) any other patents or patent applications (and resulting patents therefrom) that are in the Territory and owned or controlled by Gilead and its Affiliates during the term of this Agreement including to the extent falling within clause (b) of this definition (i) those patents and patent applications exclusively licensed by Gilead from

Japan Tobacco pursuant to the Japan Tobacco Agreement and (ii) those patents and patent applications claiming improvements or modifications to the manufacture of API, in the case of each patent and patent application referenced in clauses (a) and (b) solely to the extent necessary for Licensee to practice the licenses granted in Section 2 hereof.

“**Product**” shall mean COBI Product, EVG Product, TAF Product, TDF Product, COBI Combination Product, EVG Combination Product, TAF Combination Product, TDF Combination Product, BIC Product, BIC Combination Products, and the Quad Products.

“**Territory**” shall mean the TDF-TAF Territory, the COBI Territory, the EVG-Quad Territory, and the BIC Territory.

- b. The below terms are hereby added to Section 1 of the Agreement and are defined as follows:

“**BIC Combination Product**” shall mean a pharmaceutical product containing BIC in combination with any other active pharmaceutical ingredient other than TAF, TDF, EVG, or COBI (in each case subject to the restrictions set forth in Section 4 of this Amendment, including any co formulation, co-packaged product, bundled product, or other type of combination product.

“**BIC Product**” shall mean a formulated and finished pharmaceutical product containing BIC as its sole active pharmaceutical ingredient.

“**BIC Territory**” shall mean those countries listed on Appendix 6.

- c. All capitalized terms not otherwise defined in this Amendment shall have the meanings assigned to them in the Agreement.
2. API License. Section 2.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

“API License. Subject to the terms and conditions of this Agreement, MPP hereby grants to Licensee a royalty-free, non-exclusive, non-sublicensable (other than a sublicense to an Affiliate in accordance with Section 2.3 below), non-transferable license under the Licensed Technology to (i) make API in China solely for the purposes of exercising the licenses described in this Section 2.1; (ii) offer for sale and sell such API to Licensed Product Suppliers in India, China and South Africa for use solely for purposes set forth in the Licensed Product Suppliers’ direct or indirect license from Gilead as set forth in the definition of Licensed Product Suppliers; (iii) import Licensed API into China for purposes of exercising the license set forth in Section 2.2 or (iv) use API for Licensee’s own internal use in the applicable Territory. For clarity, the license granted in this Section 2.1 does not include, expressly or by implication, a license under any Gilead intellectual property right to manufacture, sell or distribute any active pharmaceutical ingredient owned or controlled by Gilead other than TAF, TDF, EVG, COBI, and BIC.”

3. Product License. Section 2.2 of the Agreement is hereby deleted in its entirety and replaced with the following:

“Product License. Subject to the terms and conditions of this Agreement, MPP hereby grants to Licensee a royalty-bearing, non-exclusive, non-sublicensable (other than a sublicense to an Affiliate in accordance with Section 2.3 below), non-transferable license under the Licensed Technology solely to make Product in China and sell, have sold, offer for sale, export from China and import (i) TAF Product, TAF Combination Product, TDF Product and TDF Combination Products in the Field in the TDF-TAF Territory, (ii) EVG Product, EVG Combination Products and the Quad Products in the Field in the EVG-Quad Territory, (iii) COBI Products and COBI Combination Products in the Field and in the COBI Territory, and (iv) BIC Product and BIC Combination Products in the Field and in the BIC Territory; provided that in each case such Products shall be made only from Licensed API. For clarity, (a) the licenses granted in this Section 2.2 do not include, expressly or by implication, a license under any Gilead intellectual property right to manufacture, sell or distribute any product containing active pharmaceutical ingredients owned or controlled by Gilead other than Products containing TAF, TDF, EVG, COBI, and BIC, and (b) notwithstanding the foregoing, the licenses granted under this Section 2.2 shall not extend to any active pharmaceutical ingredient included within a Product other than TAF, TDF, EVG, COBI, and BIC.”

4. Affiliates. Section 2.3 of the Agreement is hereby deleted in its entirety and replaced with the following:

“Affiliates. Licensee may grant sublicenses under the licenses granted in Section 2.1 or Section 2.2 to its Affiliates located in China upon prior written notice to Gilead and MPP. Upon Gilead’s or MPP’s request, Licensee shall provide Gilead and/or MPP (as applicable) with the written copies of the applicable sublicense agreement with such Affiliate(s). Further upon Gilead’s or MPP’s request, Licensee shall name Gilead and/or MPP (as applicable) as a third party beneficiary in any such sublicense agreement, in which case Licensee shall consent and hereby does consent to Gilead’s and/or MPP’s (as applicable) enforcement of such sublicense agreement to the extent relating to the obligations that Licensee is required hereunder to impose on its Affiliates. Licensee shall ensure that any such Affiliate complies with all the terms of this Agreement as if they were a party to this Agreement, and Licensee will be liable for the activities of such Affiliates as if such activities were performed by Licensee.”

5. Product Sales.

- a. Section 2.5(b) of the Agreement is hereby amended to delete the first paragraph of such Section which is hereby replaced with the following:

“Subject to Sections 10.3(c) and 10.3(d) of the Agreement, Licensee agrees that it will not sell, offer for sale, or assist third parties (including Affiliates) in selling Product *except for* the sale and offer for sale of (A) TAF Product, TAF Combination, TDF Product and TDF Combination Product for use in the Field in and in the countries of the TDF-TAF Territory, (B) COBI Product and COBI Combination Product for use in the Field and in the countries of the COBI Territory, (C) EVG Product, EVG Combination Product and Quad Product for use in the Field and in the countries of the EVG-Quad Territory, and (D) BIC Product and BIC Combination Product for use in the Field and in the countries of the BIC Territory.”

- b. Section 2.5(b)(ii) is hereby deleted in its entirety and replaced with the following:

“Licensee agrees that it will not administer BIC to humans, or sell Products containing BIC until Gilead has obtained marketing approval for a Product containing BIC from the FDA.”

6. Limitations on Product Combinations. Licensee will be allowed to manufacture and sell BIC in combination with other active pharmaceutical ingredients in the BIC Territory, provided in each case (A) Licensee has the legal right to manufacture and sell such other active pharmaceutical ingredients in the applicable country in the BIC Territory, and (B) such manufacture and sale is in accordance with the licenses granted herein.
7. Gilead Distributors. Section 2.5(d)(i) of the Agreement is hereby deleted in its entirety and replaced with the following:

“Licensee may elect to sell finished Product in the Territory to any Gilead Distributor, provided, however, that (A) Licensee may only sell and offer for sale TAF Product, TAF Combination Product, TDF Product and TDF Combination Product to Gilead Distributors to sell in the TDF-TAF Territory, and may not sell or offer for sale TAF Product, TAF Combination Product, TDF Product or TDF Combination Product outside the TDF-TAF Territory, and may not import TAF Product or TAF Combination Product into any country outside the TDF-TAF Territory, (B) Licensee may only sell and offer for sale COBI Product and COBI Combination Product to Gilead Distributors to sell in the COBI Territory, and may not sell or offer for sale COBI Product or COBI Combination Product outside the COBI Territory, and may not import COBI Product or COBI Combination Product into any country outside the COBI Territory, (C) Licensee may only sell and offer for sale EVG Product, EVG Combination Product and Quad Product to Gilead Distributors to sell in the EVG-Quad Territory, and may not sell or offer for sale EVG Product, EVG Combination Product or Quad Product outside the EVG-Quad Territory, and may not import EVG Product, EVG Combination Product or Quad Product into any country outside the EVG-Quad Territory, (D) Licensee may only sell and offer for sale BIC Product and BIC Combination Product to Gilead Distributors to sell in the BIC Territory, and may not sell or offer for sale BIC Product or BIC Combination Product outside the BIC Territory, and may not import BIC Product or BIC Combination Product into any country outside the BIC Territory, and (E) Licensee shall only sell to such Gilead Distributor those Products that are bioequivalent to the branded products Gilead has granted such Gilead Distributor the right to sell in such country of the applicable Territory. Licensee shall only allow such Gilead Distributor to sell such Product in the countries within the country of the applicable Territory for which such Gilead Distributor has the right to sell branded Gilead product. For example, Licensee shall not sell to a Gilead Distributor (X) a Product containing TDF, emtricitabine (FTC) and efavirenz in a particular country in the TDF-TAF Territory, unless Gilead has granted such distributor the right to sell a branded product containing TDF, FTC and efavirenz in such country in the TDF-TAF Territory, or (Y) a Product containing both TDF and 3TC or both TAF and 3TC.”

8. Third Party Reseller Agreements. Section 2.5(e) of the Agreement is hereby deleted in its entirety and replaced with the following:

“Gilead/MPP Approval of Third Party Reseller Agreements. Licensee shall not enter into any agreements with Third Party Resellers on terms inconsistent with this Agreement without obtaining Gilead’s prior written approval. If Licensee enters into an agreement with any Third

Party Reseller, then Licensee shall notify Gilead and MPP in writing, and shall certify that its arrangement with such Third Party Reseller is consistent with the terms and conditions of this Agreement. Upon Gilead's or MPP's request, Licensee shall provide Gilead and/or MPP (as applicable) with written copies of all agreements executed between Licensee and Third Party Resellers. Further upon Gilead's or MPP's request, Licensee shall name Gilead and/or MPP (as applicable) as a third party beneficiary in any such agreements, in which case Licensee shall consent and hereby does consent to Gilead's and/or MPP's (as applicable) enforcement of such agreements to the extent relating to the obligations that Licensee is required hereunder to impose upon Third Party Resellers. Gilead and/or MPP shall have the right to review all such agreements to verify consistency with the terms and conditions of this Agreement. In the event that any inconsistency is found which had not been specifically discussed and agreed with Gilead, then Gilead and/or MPP shall have the right to require Licensee to terminate such agreement. To the extent any such agreements relate to EVG, EVG Product, EVG Combination Product, or Quad Product, Gilead shall also have the right to share such agreements with Japan Tobacco."

9. Termination of Third Party Agreement by Gilead. Section 2.5(g) of the Agreement is hereby deleted in its entirety and replaced with the following:

“Termination of Third Party Agreements by Gilead. Gilead may terminate the right of Licensee to sell Product to any Third Party Reseller pursuant to this Section 2.5, if Gilead believes in good faith that the Third Party Reseller is not acting in a way that is consistent with Licensee's covenants under this Agreement, or if Licensee does not terminate Licensee's agreement with such Third Party Reseller under the circumstances described in Section 2.5(e) or Section 2.5(f).”

10. No Other Licenses. Section 2.6(d)(ii) of the Agreement is hereby deleted in its entirety and replaced with the following:

“Except as expressly set forth in this Agreement, MPP does not grant any license under any of Gilead's intellectual property rights (including, without limitation, patents or rights to any proprietary compounds or drug substances other than API) to Licensee.”

11. Sourcing of API from API Suppliers. The last sentence of Section 3.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

“In the event that any inconsistency is found which had not been specifically discussed and agreed with Gilead, each of Gilead and MPP shall have the right to require Licensee to terminate such agreement with such Gilead Supplier or Licensed API Supplier, and upon notice from Gilead and/or MPP to such effect, Licensee shall immediately terminate such agreement.”

12. Royalty. As consideration for the licenses granted in Section 2 of the Agreement, as amended by Sections 2 and 3 of this Amendment, Licensee shall pay Gilead the following royalties on Net Sales of BIC Product and BIC Combination Product in the Territory for the duration of the Royalty Term:

- a. 5% of BIC Product Net Sales in the BIC Territory.

- b. 5% of the portion of BIC Combination Product Net Sales attributable to the BIC component of such BIC Combination Product in the BIC Territory, as determined in accordance with Section 4.2 of the Agreement.
 - c. To the extent any TAF Combination Product, TDF Combination Product, EVG Combination Product, and/or COBI Combination Product contains BIC, then in addition to royalties due from Licensee to Gilead for each other royalty bearing API in such Combination Product as set forth in Section 4.1(c), (f) and (h) of the Agreement, respectively, Licensee will pay Gilead 5% of the portion of such Combination Products Net Sales attributable to the BIC component of such Combination Product in the Territory applicable to such Combination Product, as determined in accordance with Section 4.2 of the Agreement.
13. Quarterly Reports. In each Quarterly Report, Licensee shall provide Gilead with the following information (in addition to the information described in Section 4.3 of the Agreement): (i) any Drug Controller General of India export permits obtained by the Licensee for Product, including the quantity of Product exported, the final destination of the Product and the recipient of the Product; and (ii) any Central Drugs Standard Control Organization (CDSCO) No Objection Certificates (NOC) obtained by third parties for Product for which Licensee provided assistance, including the quantity of Product exported, the final destination of the Product and the recipient of the Product.
14. Cooperation. If any party becomes aware of a suspected occurrence of any prohibited activity described in Section 7.2(a)(i)-(viii), such party will notify the other parties promptly, and following such notification, the parties will confer. Gilead (except in the case of Patents relating to EVG, EVG Product, EVG Combination Product or TAF Quad that are subject to the Japan Tobacco Agreement and controlled by Japan Tobacco) will have the right, but not the obligation, to bring an infringement or other action at its own expense, in its own name, and entirely under its own direction and control. Licensee will reasonably assist Gilead (or, where applicable, Japan Tobacco) in such actions or proceedings if so requested, and will lend its name to such actions or proceedings if required by law in order for Gilead (or Japan Tobacco) to bring such an action, which obligations shall survive the expiration or termination of the Agreement.
15. Manufacturing Requirements Minimum Standards. Section 6.2(a) of the Agreement is hereby deleted in its entirety and replaced with the following:

“Minimum Standards.

(i) Licensee agrees that it shall manufacture API and Product in a manner consistent with (i) the applicable Indian manufacturing standards; (ii) either World Health Organization (“WHO”) pre-qualification standards, standards of the European Medicines Agency (“EMA”), or United States Food and Drug Administration (“FDA”) tentative approval standards (“**Minimum Quality Standards**”); and (iii) on a country-by-country basis, any applicable national, regional or local standards as may be required by the specific country where Product is sold.

(ii) As required by MPP, in the event that any of COBI, EVG, TAF or BIC are included in the *WHO Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing*

HIV infection (“**WHO Guidelines**”) or in the expression of interest for WHO pre-qualification for active pharmaceutical ingredients, Licensee shall apply for WHO pre-qualification or submit such included API’s Drug Master File (or equivalent) to the FDA no later than by the second anniversary of any such inclusion.

(iii) As required by MPP, in the event that any TAF Product or TAF Combination Product, BIC Product or BIC Combination Product, COBI Product or COBI Combination Product, EVG Product or EVG Combination Product, or the TDF Quad are included in WHO Guidelines or in the expression of interest for WHO pre-qualification of medicines, Licensee shall apply for WHO pre-qualification or FDA conditional approval for each such Product so included no later than by the third anniversary of any such inclusion.”

16. Remedy for Failure. Section 6.2(c) of the Agreement is hereby deleted in its entirety and replaced with the following:

“Remedy for Failure. If Licensee fails at any time to meet the Minimum Quality Standards with respect to the manufacture of API or Product, Gilead and/or MPP may elect, in their sole discretion and notwithstanding Section 10.2 or 10.3 hereof, to suspend the effectiveness of the licenses granted hereunder until such time as Gilead and/or MPP have determined that Licensee has corrected any such failure to Gilead’s and/or MPP’s reasonable satisfaction. During any such suspension, Gilead and/or MPP and Licensee shall coordinate with each other to provide for the supply of API or Product, as appropriate, to ensure that end-user patient requirements are not disrupted as a result of such suspension.”

17. Dose Requirements. All BIC Product and BIC Combination Products manufactured, used or sold by Licensee shall consist of dose concentrations of BIC that have been approved by the FDA. In the case of Products containing BIC, Licensee may manufacture or sell BIC Product, or BIC Combination Product consisting of an Alternate Dosage if such Alternate Dosage has been approved for use in the Field by the appropriate regulatory authority having jurisdiction over such Product.

18. Pediatric Formulations. Licensee will have the right to develop a BIC Product or BIC Combination Product as either a liquid or dispersible tablet formulation for use in pediatric patients less than 12 years of age (such formulation shall be a Pediatric Formulation). If Licensee is granted regulatory approval to market such Pediatric Formulation, then Licensee will use reasonable efforts to make such Pediatric Formulation available throughout the BIC Territory (for purposes of Section 6.2(e) of the Agreement, the BIC Territory shall be Licensee’s Applicable Territory with respect to such Pediatric Formulation).

19. Regulatory Filings and Inspections. To the extent Regulatory Reports relate to EVG, EVG Product, EVG Combination Product, or Quad Product, Gilead will have the right to share such Regulatory Reports with Japan Tobacco, which right shall survive the expiration or termination of the Agreement.

20. Safety Reporting. The following language is hereby added to the Agreement as Section 6.6:

“Safety Reporting.

- a. Licensee is responsible for all single and periodic reporting to all applicable regulatory authorities for the Products manufactured by or on behalf of Licensee under the Agreement.
- b. Licensee is responsible for all pharmacovigilance activities with respect to such Products, including but not limited to all associated signal detection, risk management and product labelling requirements.
- c. In the event Licensee receives an individual case safety report associated with any Gilead proprietary product, Licensee agrees to forward such reports to Gilead at E-Mail: SafetyFC@gilead.com Fax: +1-650-522-5477.
- d. Licensee will forward details of any confirmed safety signals or emerging safety issues relating to Products manufactured by or on behalf of Licensee under this Agreement and any supporting documentation to the risk management contact at Gilead: Neda.Shokrai@gilead.com.”

21. Diversion of Product and Technology. Section 7.2 of the Agreement is hereby deleted in its entirety and replaced with the following:

“Diversion of Product and Technology.

- (a) Licensee covenants and agrees that Licensee and its Affiliates shall not, and shall require its Distributors and Third party Resellers not to: (i) divert or allow the diversion of API outside of India, China or South Africa, or to third parties that do not constitute Licensed Product Suppliers, (ii) divert or allow the diversion of TDF Product, TDF Combination Product, TAF Product or TAF Combination Product outside the TDF-TAF Territory, (iii) divert or allow the diversion of COBI Product or COBI Combination Product outside the COBI Territory, (iv) divert or allow the diversion of EVG Product, EVG Combination Product or Quad Product outside the EVG-Quad Territory, (v) divert or allow the diversion of BIC Product or BIC Combination Product outside the BIC Territory, (vi) divert or allow the diversion of Licensed Technology to any third party, except as expressly permitted under this Agreement, (vii) take any action that Gilead determines in good faith to be in furtherance of the activities described in clauses (i) – (vi), or (viii) assist or support, directly or indirectly, any third party in the conduct of the activities described in clauses (i) - (vii). The parties agree that it shall not be a breach of Section 3.1 or this Section 7.2 for Licensee or its Affiliate to file marketing approval applications for any Product in a country outside of the Territory as required by applicable regulatory authorities in such country for the commercialization of such Product in such country, or for Licensee or its Affiliate to provide developmental quantities of API or Product in support of its own marketing approval applications or a third party’s application for marketing approval, in each case, as required by applicable regulatory authorities in such country, it being understood that this provision shall not be construed as expressly or implicitly granting Licensee any right or license under any Gilead intellectual property rights beyond the licenses granted in Section 2 of this Agreement or otherwise providing any authorization by Gilead to do so, and does not constitute a waiver of any rights of Gilead under law that it may have to contest the filing or granting of such marketing approval applications.”

(b) Damages. In the event (i) any Product is diverted (x) by Licensee or its Affiliate sublicensees, or (y) by another party with the assistance of the Licensee or its Affiliate sublicensees, in each case to any country outside the Territory in any manner described in Section 7.2(a), and (ii) a patent covering such Product has been granted in such country or in the country(ies) outside the Territory in which such Product is manufactured (collectively the circumstance described by clause (i) and (ii), a “**Diversions Event**”), then in addition to any other remedies Gilead may be entitled to at law or in equity, Gilead shall be entitled to injunctive relief and to receive lost profits associated with the Diversions Event, which such lost profits will be determined by taking into consideration the following factors: (1) the quantity of Product that is the subject of such Diversions Event; (2) the average profit Gilead receives from its sale of such Product in the country(ies) outside the Territory into which such Product was sold or otherwise transferred; and (3) any erosion in Gilead’s market share in such country(ies) outside the Territory as a result of such Diversions Event. This Section 7.2(b) shall survive the expiration or termination of the Agreement with respect to Products sold prior to such expiration or termination.”

22. General Law Compliance. Section 7.3(a) of the Agreement is hereby deleted in its entirety and replaced with the following:

“General Law Compliance. Licensee covenants and agrees that it shall perform all activities under this Agreement in accordance with all applicable laws, rules, and regulations, including, without limitation, with respect to privacy, data protection, recalls, safety and reporting requirements and shall obtain, have and maintain all necessary regulatory approvals (including in China), marketing authorizations, permits and licenses, at Licensee’s expense for the manufacture and sale of API and/or Product and any other Licensee activities contemplated hereby.”

23. FCPA and UK Bribery Act. Section 7.3(b) of the Agreement is hereby deleted in its entirety and replaced with the following:

“FCPA and UK Bribery Act. Licensee covenants and agrees that neither the Licensee, nor any of its affiliates, nor any of their respective directors, officers, employees or agents (all of the foregoing, including affiliates collectively, “**Licensee Representatives**”) has taken any action, directly or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended (such act, including the rules and regulations thereunder, the “**FCPA**”), the U.K. Bribery Act of 2010 (“**Bribery Act**”), or any other applicable anti-bribery or anticorruption laws, rules or regulations (collectively with the FCPA and the Bribery Act, the “**Anticorruption Laws**”). Licensee covenants and agrees that Licensee and Licensee Representatives have conducted and will conduct their businesses in compliance with the Anticorruption Laws. Licensee covenants and agrees that it shall provide to Gilead on the Amendment Effective Date and within thirty (30) days after the beginning of each calendar year thereafter, certification in writing by Licensee of Licensee’s compliance with the Anticorruption Laws.”

24. Gilead Right to Terminate. Section 10.3(b) of the Agreement is hereby deleted in its entirety and replaced with the following:

“(b) Gilead and/or MPP shall have the right to terminate this Agreement, the covenant contained in Section 7.5 and/or one or both of the licenses granted pursuant to Section 2.1 or Section 2.2 (whether or not such event constitutes a right of termination pursuant to Section 10.2), if:

(i) Gilead determines in good faith that (A) a material quantity of API made or sold by Licensee has been diverted outside of South Africa, China or India, or to third parties that are not Licensed Product Suppliers, (B) a material quantity of Product made and/or sold by Licensee has been diverted to countries outside the Territory (other than with respect to such diversions occurring solely as a result of the circumstances expressly contemplated in Sections 7.3(c), 10.3(c) and 10.3(d) below), or (C) any of the prohibited activities described in Section 7.2(a)(i)-(viii) has occurred;

(ii) Gilead and/or MPP determines in good faith that, due to material deficiencies in Licensee’s compliance, or repeated failure to comply, with the Minimum Quality Standards, Licensee is unable to reliably and consistently manufacture API or Product in accordance with the Minimum Quality Standards;

(iii) Gilead determines in good faith that Licensee has obtained material quantities of API from sources outside of India, South Africa or China (subject to the provisions set forth in Sections 7.3(c) and 10.3(c)), or in ways that are inconsistent with the terms and conditions of Section 3; or

(iv) Gilead’s rights to EVG terminate due to the termination of the Japan Tobacco Agreement, provided, however, that in such event, such termination would only apply on a Product-by-Product basis and only with respect to Products containing EVG that are subject to the sublicense granted by Gilead under the Japan Tobacco Agreement.

Gilead shall give Licensee and MPP written notice of any such event and provide Licensee with a period of thirty (30) days after such notice to demonstrate that the conditions giving rise to Gilead’s determination no longer exist to Gilead’s reasonable satisfaction. If Licensee is unable to do so, this Agreement shall be terminated effective upon the thirtieth (30th) day following such notice. In the event that MPP independently exercises its right to terminate this Agreement pursuant to Sections 10.2 or 10.3, MPP shall provide notice to Gilead of such intent to terminate.”

25. Licensee Right to Terminate License on an API Basis. For the avoidance of doubt any termination by Licensee of its license to BIC pursuant to Section 10.5 of the Agreement shall in turn terminate Licensee’s rights and licenses under all Patents that claim BIC (alone or in combination with any other compounds) to manufacture, sell, use, export or import any Product that contains BIC.
26. Appendices. Appendices 1, 2, 3, 4, and 5 of the Agreement are hereby deleted and replaced with new Appendices 1, 2, 3, 4, and 5 attached to this Amendment, respectively. Appendix 6 attached to this Amendment is hereby added to the Agreement as Appendix 6.
27. Miscellaneous. This Amendment embodies the entire understanding of the Parties with respect to the subject matter hereof and supersedes all previous communications, representations or understandings, and agreements, whether oral or written, between the Parties relating to the subject matter hereof. Except as expressly amended by this Amendment, the terms and

conditions of the Agreement will remain in full force and effect. This Amendment shall be effective as of the Amendment Effective Date, and may not be modified except by written agreement between the Parties. This Amendment will be governed by and construed under the laws of Hong Kong, without regard to its choice of law principles, and any dispute that arises hereunder shall be resolved by binding arbitration as set forth in Section 12.7 of the Agreement.

[signatures appear on following page]

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Amendment Effective Date.

GILEAD:

Gilead Sciences, Inc.

By _____
Name:
Title:

LICENSEE:

By _____
Name:
Title:

MPP:

Medicines Patent Pool

By _____
Name:
Title:

APPENDIX 1

Countries in the TDF-TAF Territory

1. Afghanistan
2. Angola
3. Anguilla
4. Antigua and Barbuda
5. Armenia
6. Aruba
7. Bahamas
8. Bangladesh
9. Barbados
10. Belarus
11. Belize
12. Benin
13. Bhutan
14. Bolivia
15. Botswana
16. British Virgin Islands
17. Burkina Faso
18. Burundi
19. Cambodia
20. Cameroon
21. Cape Verde
22. Central African Republic
23. Chad
24. Comoros
25. Congo, Rep
26. Congo, Dem. Rep. of the
27. Côte d'Ivoire
28. Cuba
29. Djibouti
30. Dominica
31. Dominican Republic
32. Ecuador
33. El Salvador
34. Equatorial Guinea
35. Eritrea
36. Ethiopia
37. Fiji Islands
38. Gabon
39. Gambia
40. Georgia
41. Ghana
42. Grenada
43. Guatemala
44. Guinea
45. Guinea-Bissau
46. Guyana
47. Haiti
48. Honduras
49. India
50. Indonesia
51. Jamaica
52. Kazakhstan
53. Kenya
54. Kiribati
55. Kyrgyzstan
56. Lao, People's Dem. Rep.
57. Lesotho
58. Liberia
59. Madagascar
60. Malawi
61. Malaysia
62. Maldives
63. Mali
64. Mauritania
65. Mauritius
66. Moldova, Rep. of
67. Mongolia
68. Montserrat
69. Mozambique
70. Myanmar
71. Namibia
72. Nauru
73. Nepal
74. Nicaragua
75. Niger
76. Nigeria
77. Pakistan
78. Palau
79. Papua New Guinea
80. Philippines
81. Rwanda
82. Saint Kitts and Nevis
83. Saint Lucia
84. Saint Vincent & the Grenadines
85. Samoa
86. São Tomé and Príncipe
87. Senegal
88. Seychelles
89. Sierra Leone
90. Solomon Islands
91. Somalia
92. South Africa
93. South Sudan
94. Sri Lanka
95. Sudan
96. Surinam
97. Swaziland
98. Syrian Arab Republic
99. Tajikistan
100. Tanzania, U. Rep. of
101. Thailand
102. Timor-Leste
103. Togo
104. Tonga
105. Trinidad and Tobago
106. Turkmenistan
107. Turks and Caicos
108. Tuvalu
109. Uganda
110. Ukraine
111. Uzbekistan
112. Vanuatu
113. Vietnam
114. Yemen
115. Zambia
116. Zimbabwe

APPENDIX 2

Patents

TDF Patents

(221) Title: NUCLEOTIDE ANALOGS

Country	Status	Filing Date	Application No.	Patent No.	Issue Date
China (People's Republic)	Granted	7/25/1997	200810083233.70	200810083233.70	12/12/2012
China (People's Republic)	Granted	7/25/1997	97197460.8	ZL97197460.8	4/30/2008
India	Pending	7/25/1997	2076/DEL/1997		

(230) Title: NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD

SubCase	Status	Filing Date	Application No.	Patent No.	Issue Date
China (People's Republic)	Granted	7/23/1998	200510099916.80	ZL200510099916.8	9/24/2008
China (People's Republic)	Granted	7/23/1998	200410046290X	200410046290X	4/19/2006
India	Pending	7/24/1998	896/DEL/2002		
India	Pending	7/24/1998	963/DEL/2002		
India	Pending	7/24/1998	1362/DEL/2004		
India	Granted	7/24/1998	2174/DEL/1998	190780	3/15/2004
Indonesia	Granted	7/23/1998	W-991548	7658	4/11/2002

(270) Title: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Country	Status	Filing Date	Application No.	Patent No.	Issue Date
Armenia	Granted	1/13/2004	200501134	15145	6/13/2011
China (People's Republic)	Published	1/13/2004	201510697340.90		
China (People's Republic)	Granted	1/13/2004	201210094391.90	ZL201210094391.9	2/24/2016
China (People's Republic)	Granted	1/13/2004	200480002190.50	200480002190.50	6/6/2012
Eurasian Patent Organization	Published	1/13/2004	201100293		
Eurasian Patent Organization	Granted	1/13/2004	200501134	15145	6/13/2011
Kazakhstan	Granted	1/13/2004	200501134	15145	6/13/2011
Kazakhstan	Pending		200501134 (PTE Application)		

Kyrgyz Republic	Granted	1/13/2004	200501134	15145	6/13/2011
Kyrgyz Republic	Granted		200501134 (PTE Application)	15145	5/31/2012
Moldova	Granted	1/13/2004	200501134	15145	6/13/2011
Tajikistan	Granted	1/13/2004	200501134	15145	6/13/2011
Turkmenistan	Granted	1/13/2004	200501134	15145	6/13/2011
Turkmenistan	Pending		200501134 (PTE Application)		

(676) Title: METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT

Country	Status	Filing Date	Application No.	Patent No.	Issue Date
China (People's Republic)	Granted	6/13/2006	200680026180.40	ZL200680026180.4	10/7/2015

(677) Title: A PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARING THEREOF, AND A METHOD OF TREATING VIRAL DISEASES USING SAID COMPOSITION

Country	Status	Filing Date	Application No.	Patent No.	Issue Date
Armenia	Granted	6/13/2006	200800033	17764	3/29/2013
China (People's Republic)	Granted	6/13/2006	200680026866.30	200680026866.30	3/27/2013
Eurasian Patent Organization	Published	6/13/2006	201201265		
Eurasian Patent Organization	Granted	6/13/2006	200800033	17764	3/29/2013
India	Pending	6/13/2006	9661/DELNP/2007		
Kazakhstan	Granted	6/13/2006	200800033	17764	3/29/2013
Kyrgyz Republic	Granted	6/13/2006	200800033	17764	3/29/2013
Moldova	Granted	6/13/2006	200800033	17764	3/29/2013
South Africa	Granted	6/13/2006	2008/00297	2008/00297	4/28/2010
Tajikistan	Granted	6/13/2006	200800033	17764	3/29/2013
Turkmenistan	Granted	6/13/2006	200800033	17764	3/29/2013

TAF Patents

(249) Title: PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
African Intellectual Property	Granted	1200300003	7/20/2001	12393	12/29/2003

Organization (OAPI)					
African Regional Industrial Property Organization	Granted	2003/002724	7/20/2001	AP 1466	9/22/2005
Anguilla	Granted	AI/A/2015/00173	7/20/2001	AI/A/2015/00173	11/2/2015
China (People's Republic)	Granted	1813161.1	7/20/2001	ZL01813161.1	12/27/2006
China (People's Republic)	Granted	200410097845.30	7/20/2001	ZL200410097845.3	7/16/2008
Congo, Democratic Republic of	Granted	NP/002/EXT/2016	7/20/2001	2016/4386	11/11/2016
Ethiopia	Granted	ET/PI/15/184	7/20/2001	135	5/25/2016
Eurasian Patent Organization	Granted	200300188	7/20/2001	4926	10/28/2004
Falkland Islands (Malvinas)	Granted		7/20/2001	15365	8/25/2015
Fiji	Published	1214	7/20/2001		
Grenada	Granted	7 of 2015	7/20/2001	7 of 2015	10/6/2015
Guyana	Published	1641	7/20/2001		
Haiti	Pending		7/20/2001		
India	Granted	9/MUMNP/2003	7/20/2001	208435	7/27/2007
India	Granted	00529/MUMNP/2006	7/20/2001	241597	7/14/2010
Indonesia	Granted	W-00200602129	7/20/2001	IDP0022897	2/20/2009
Indonesia	Granted	W-00200804005	7/20/2001	IDP000040148	2/15/2016
Indonesia	Granted	W00200300261	7/20/2001	IDP0022911	2/20/2009
Jamaica	Pending	18/1/5695	7/20/2001		
Kiribati	Granted	14/15	7/20/2001	14/15	10/7/2015
Montserrat	Granted	1961695.2	7/20/2001	1301519	9/23/2015
Nepal	Pending	669	7/20/2001		
Seychelles	Granted	1301519	7/20/2001	1301519	5/25/2016
Sierra Leone	Pending	EP1301519	7/20/2001		
Solomon Islands	Granted	J37/371	7/20/2001	J37/371	3/3/2016
South Africa	Granted	2002/10271	7/20/2001	2002/10271	12/31/2003
Turks and Caicos Islands	Pending	10213	7/20/2001		
Tuvalu	Granted		2/25/2015	TVP1301519	1/6/2016
Vietnam	Granted	1-2002-01193	7/20/2001	8475	5/24/2010
Virgin Islands (British)	Granted	414/5/2015	7/20/2001	414/5/2015	12/1/2015

(872) Title: TENOFOVIR ALAFENAMIDE HEMIFUMARATE

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
African Intellectual Property Organization (OAPI)	Granted	1201400057	8/15/2012	17070	6/29/2015
African Regional Industrial Property Organization	Granted	AP/P/2014/007437	8/15/2012	3639	3/31/2016
Bahamas	Granted	2441	8/15/2012	2441	6/19/2014
Bolivia	Pending	SP-0277-2012	8/15/2012		
China (People's Republic)	Published	201280039891.00	8/15/2012		
Ecuador	Pending	SP-14-13206-PCT	8/15/2012		
El Salvador	Pending	E-4659-2014	8/15/2012		
Eurasian Patent Organization	Published	201490208	8/15/2012		
India	Pending	1012/DELNP/2014	8/15/2012		
Indonesia	Published	P00201400805	8/15/2012		
Moldova	Pending	A20140011	8/15/2012		
Pakistan	Pending	539/2012	8/15/2012		
Philippines	Granted	1-2014-500349	8/15/2012	1-2014-500349	2/29/2016
South Africa	Allowed	2014/00582	8/15/2012		
Thailand	Pending	1401000784	8/15/2012		
Vietnam	Pending	1-2014-00440	8/15/2012		

(877) Title: METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Bahamas	Granted	2455	10/3/2012	2455	6/24/2014
Bolivia	Granted	SP-0352-2012	10/3/2012	6385-B	11/26/2014
China (People's Republic)	Published	201280048965.70	10/3/2012		
Ecuador	Published	IEPI-2014-74	10/3/2012		
El Salvador	Published	E-4696/2014	10/3/2012		
Eurasian Patent Organization	Allowed	201490753	10/3/2012		
India	Published	2953/DELNP/2014	10/3/2012		
Pakistan	Pending	671/2012	10/3/2012		

EVG Patents

(JF-0136) Title: COMPOUND AND METHOD OF USE

Country	Status	Application No.	Filing Date	Patent No.
---------	--------	-----------------	-------------	------------

Bolivia	Pending	SP-230265	11/18/2003		
China (People's Republic)	Granted	200380100277.10	11/20/2003	ZL200380100277.1	3/19/2008
India	Granted	01316/CHENP/2004	11/20/2003	245833	2/3/2011
Indonesia	Granted	WO00200401542	11/20/2003	P0023507	6/1/2009
Nigeria	Granted	424/2003	11/19/2003	RP.15779	10/20/2004
Philippines	Granted	1-2004-500895	11/20/2003	1-2004-500895	8/20/2008
South Africa	Granted	2004/4537	11/20/2003	2004/4537	8/31/2005
Thailand	Pending	301004379	11/20/2003		
Vietnam	Granted	1-2004-00605	11/20/2003	1-0011884	10/7/2013

(JF-0179) Title: CRYSTALLINE FORM

Country	Status	Application No.	Filing Date	Patent No.	
Bolivia	Pending	SP-250121	5/19/2005		
China (People's Republic)	Granted	200580016142.60	5/19/2005	ZL200580016142.6	5/26/2010
India	Pending	357/CHENP/2010	5/19/2005		
Philippines	Granted	1-2006-502297	5/19/2005	1-2006-502297	11/19/2010
South Africa	Granted	2006/10647	5/19/2005	2006/10647	6/25/2008
Thailand	Pending	100718	5/19/2005		

(JF-0193) Title: MANUFACTURING PROCESS: ROUTE D AND F

Country	Status	Application No.:	Filing Date	Patent No.	Issue Date
China	Granted	200780016151.40	3/6/2007	200780016151.40	2/6/2013
India	Granted	5344/CHENP/2008	3/6/2007	258895	2/13/2014
India	Pending	532/CHENP/2014	3/6/2007		

(JF-0192) Title: MANUFACTURING PROCESS: ROUTE C AND E

Country	Status	Application No.	Filing Date	Patent No:	Issue Date
African Regional Industrial Property Organization	Granted	AP/P/2008/004621	3/6/2007	2914	5/5/2014
China	Granted	200780016172.60	3/6/2007	ZL200780016172.60	5/29/2013
Eurasian Patent Organization	Granted	200870321	3/6/2007	17861	3/29/2013
Indonesia	Pending	W00200802860	3/6/2007	IDP0032077	10/22/2012
India	Granted	5341/CHENP/2008	3/6/2007	258747	2/4/2014
India	Pending	613/CHENP/2014	3/6/2007		

African Intellectual Property Organization (OAPI)	Granted	1200800317	3/6/2007	14280	3/31/2009
Vietnam	Granted	1-2008-02431	3/6/2007	14450	8/17/2015
South Africa	Granted	2008/07547	3/6/2007	2008/07547	11/25/2009

(718) Title: METHODS OF IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS

Country	Status	Application No.	Filing Date	Patent No.	
Armenia	Granted	200801619	12/29/2006	18544	8/30/2013
African Regional Industrial Property Organization	Granted	AP/P/2008/004522	12/29/2006	AP2702	7/31/2013
China (People's Republic)	Published	201410249622.80	12/29/2006		
Eurasian Patent Organization	Granted	200801619	12/29/2006	18544	8/30/2013
Eurasian Patent Organization	Published	201201496	12/29/2006		
Indonesia	Pending	W00201102461	12/29/2006		
Indonesia	Published	W00 2008 02128	12/29/2006		
India	Pending	6748/DELNP/2015	12/29/2006		
India	Pending	5576/DELNP/2008	12/29/2006		
Kyrgyz Republic	Granted	200801619	12/29/2006	18544	8/30/2013
Moldova	Granted	200801619	12/29/2006	18544	8/30/2013
African Intellectual Property Organization (OAPI)	Granted	1200800239	12/29/2006	14320	6/30/2009
Tajikistan	Granted	200801619	12/29/2006	18544	8/30/2013
Turkmenistan	Granted	200801619	12/29/2006	18544	8/30/2013
Vietnam	Pending	1-2008-01921	12/29/2006		
South Africa	Granted	2008/06222	12/29/2006	2008/06222	3/25/2009

(720) Title: PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS

Country	Status	Application No.	Filing Date	Patent Number	Issue Date
Armenia	Granted	200900441	9/11/2007	22099	11/30/2015
African Regional Industrial Property Organization	Granted	AP/P/2009/004831	9/11/2007	AP3004	10/16/2014
China	Granted	200780033907.60	9/11/2007	ZL200780033907.6	10/16/2013
China	Granted	201210224990.80	9/11/2007	CN102766098B	3/30/2016

China	Abandoned	201510922236.50	9/11/2007		
China	Published	201510922511.30	9/11/2007		
Eurasian Patent Organization	Granted	200900441	9/11/2007	22099	11/30/2015
Indonesia	Published	W00200900634	9/11/2007		
Kyrgyz Republic	Granted	200900441	9/11/2007	22099	11/30/2015
Kazakhstan	Granted	200900441	9/11/2007	22099	11/30/2015
Moldova	Granted	200900441	9/11/2007	22099	11/30/2015
African Intellectual Property Organization (OAPI)	Granted	1200900070	9/11/2007	14458	9/30/2009
Thailand	Published	701004583	9/11/2007		
Tajikistan	Granted	200900441	9/11/2007	22099	11/30/2015
Turkmenistan	Granted	200900441	9/11/2007	22099	11/30/2015
Vietnam	Granted	1-2009-00636	9/11/2007	11932	10/22/2013
Vietnam	Granted	1-2012-01354	9/11/2007	14698	10/20/2015
South Africa	Granted	2009/01576	9/11/2007	2009/01576	2/24/2010

(746) Title: PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS

Country	Status	Application No	Filing Date	Patent Number	Issue Date
African Regional Industrial Property Organization	Granted	AP/P/2010/005187	9/11/2008	AP 2785	10/31/2013
China	Granted	200880106554.20	9/11/2008	ZL200880106554.2	7/9/2014
Eurasian Patent Organization	Granted	201070256	9/11/2008	19431	3/31/2014
Ecuador	Inactive	SP-10-10081	9/11/2008		
Indonesia	Published	W00201000759	9/11/2008		
India	Pending	1615/DELNP/2010	9/11/2008		
African Intellectual Property Organization (OAPI)	Granted	1201000093	9/11/2008	15058	
Thailand	Published	801004676	9/11/2008		
Vietnam	Granted	1-2010-00483	9/11/2008	10866	11/20/2012
South Africa	Granted	2010/02066	9/11/2008	2010/02066	12/29/2010

(903) Title: PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS

Country	Status	Application No.	Filing Date	Patent No.
China (People's Republic)	Granted	201380041287.60	8/1/2013	ZL201380041287.6 11/2/2016
Eurasian Patent Organization	Allowed	201590018	8/1/2013	
India	Pending	1688/DELNP/2015	8/1/2013	

COBI Patents

(692) Title: MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Granted	1200800450	9/30/2009	14409
African Regional Industrial Property Organization	Granted	AP/P/2008/004720	9/30/2014	AP2985
Anguilla	Granted	AI/A/2015/00172	11/2/2015	AI/A/2015/00172
Armenia	Granted	200900155	11/28/2014	20489
China (People's Republic)	Granted	200780025607.30	5/29/2013	ZL200780025607.3
China (People's Republic)	Granted	201310141408.60	4/29/2015	ZL201310141408.6
Congo, Democratic Republic of	Pending	NP/004/EXT/2016		
Ethiopia	Granted	ET/PI/15/185	5/25/2016	134
Eurasian Patent Organization	Allowed	201270738		
Eurasian Patent Organization	Granted	200900155	11/28/2014	20489
Fiji	Published	1217		
Guyana	Published	1642		
Haiti	Pending			
India	Pending	10487/DELNP/2008		
Indonesia	Granted	W00200900061	8/12/2016	IDP00042227
Jamaica	Pending	18/1/5696		
Kazakhstan	Granted	200900155	11/28/2014	20489
Kiribati	Granted	13/15	10/7/2015	13/15
Kyrgyz Republic	Granted	200900155	11/28/2014	20489
Moldova	Granted	200900155	11/28/2014	20489
Montserrat	Granted		9/23/2015	3 of 2015
Nauru	Pending			
Nepal	Pending	894		
Seychelles	Granted	2049506	5/25/2016	2049506
Sierra Leone	Pending	EP2049506		
Solomon Islands	Granted	J37/370	2/10/2016	J37/370
South Africa	Pending	2008/10399		

Tajikistan	Granted	200900155	11/28/2014	20489
Thailand	Published	701003404		
Turkmenistan	Granted	200900155	11/28/2014	20489
Turks and Caicos Islands	Pending	10214		
Tuvalu	Granted		11/7/2015	TVP2049506
Vanuatu	Unfiled			
Vietnam	Pending	1-2009-00240		
Vietnam	Pending	1-2012-02702		
Virgin Islands (British)	Granted	415/6/2015	12/1/2015	415/6/2015

(719) Title: MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Granted	1200900273	6/30/2010	14749
African Regional Industrial Property Organization	Granted	AP/P/2009/004964	9/16/2014	AP2986
African Regional Industrial Property Organization	Granted	AP/P/2013/007042	11/30/2016	AP3915
Armenia	Granted	200901155	7/30/2014	19893
China (People's Republic)	Granted	201310326757.50	6/10/2015	10326757
China (People's Republic)	Granted	200880013255.40	8/28/2013	ZL200880013255.4
Eurasian Patent Organization	Granted	200901155	7/30/2014	19893
Fiji	Granted			
Indonesia	Granted	W00200902299	3/18/2015	IDP000038076
Kazakhstan	Granted	200901155	7/30/2014	19893
Kyrgyz Republic	Granted	200901155	7/30/2014	19893
Moldova	Granted	200901155	7/30/2014	19893
South Africa	Pending	2009/05882		
South Africa	Unfiled			
Tajikistan	Granted	200901155	7/30/2014	19893
Thailand	Pending	801000867		
Turkmenistan	Granted	200901155	7/30/2014	19893
Vietnam	Pending	1-2009-01990		
Vietnam	Pending	1-2012-02696		

(757) Title: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT

Country	Status	Application No.	Filing Date	Patent No.
---------	--------	-----------------	-------------	------------

African Intellectual Property Organization (OAPI)	Granted	1201000364	9/28/2012	15589
African Regional Industrial Property Organization	Granted	AP/P/2010/005429	1/30/2015	3209
Armenia	Granted	201071173	3/31/2016	22950
Belarus	Granted	201071173	3/31/2016	22950
China (People's Republic)	Published	201510408376.00		
China (People's Republic)	Published	201310447258.10		
Ecuador	Pending	SP-10-10636		
Eurasian Patent Organization	Published	201591353		
Eurasian Patent Organization	Granted	201071173	3/31/2016	22950
India	Pending	7565/DELNP/2010		
Indonesia	Published	W00201004105		
Kazakhstan	Granted	201071173	3/31/2016	22950
Kyrgyz Republic	Granted	201071173	3/31/2016	22950
Moldova	Granted	201071173	3/31/2016	22950
South Africa	Granted	2010/08007	10/26/2011	2010/08007
Tajikistan	Granted	201071173	3/31/2016	22950
Turkmenistan	Granted	201071173	3/31/2016	22950
Vietnam	Pending	1-2010-02929		

(775) Title: METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED

Country	Status	Application No.	Filing Date	Patent No.
African Regional Industrial Property Organization	Granted	AP/P/2011/005864		
African Intellectual Property Organization (OAPI)	Granted	1201100311.00	4/1/2010	15801
Bolivia	Published	SP-0082-2010	4/1/2010	
China	Granted	201080014307.70	4/1/2010	ZL201080014307.7
China	Published	201510160505.90	4/1/2010	
Eurasian Patent Organization	Granted	201190179.00	4/1/2010	22739
Eurasian Patent Organization	Published	201590979.00	4/1/2010	
Ecuador	Pending	SP-11-11391	4/1/2010	
Indonesia	Granted	W00201103554	4/1/2010	IDP000041448
India	Pending	7323/DELNP/2011	4/1/2010	
Pakistan	Pending	262/2010	3/31/2010	
Thailand	Published	1101002473.00	4/1/2010	
Vietnam	Pending	1-2011-02324	4/1/2010	
South Africa	Granted	2011/07430	4/1/2010	2011/07430

(783) Title: TABLETS FOR COMBINATION THERAPY

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Pending	1201100281		
African Regional Industrial Property Organization	Granted	AP/P/2011/05857	5/6/2015	AP3250
Armenia	Granted	201190125	5/29/2015	21313
Azerbaijan	Granted	201190125	5/29/2015	21313
Bolivia	Pending	SP-00292010		
China (People's Republic)	Granted	201080006646.00	9/11/2013	ZL201080006646.0
Ecuador	Pending	SP-11-11307		
Eurasian Patent Organization	Published	201491658		
Eurasian Patent Organization	Granted	201190125	5/29/2015	21313
India	Pending	5823/DELNP/2011		
Indonesia	Granted	W00201103098	3/30/2016	IDP000040606
Kazakhstan	Granted	201190125	5/29/2015	21313
Kyrgyz Republic	Granted	201190125	5/29/2015	21313
Moldova	Granted	201190125	5/29/2015	21313
Pakistan	Allowed	94/2010		
Singapore	Published	2014007744		
South Africa	Granted	2011/06154	5/28/2014	2011/06154
Tajikistan	Granted	201190125	5/29/2015	21313
Thailand	Published	1101001423		
Turkmenistan	Granted	201190125	5/29/2015	21313
Vietnam	Pending	1-2011-02035		

(895) Title: METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS

Country	Status	Application No.	Filing Date	Patent No.
China	Abandoned	201380007712.X		
India	Abandoned	6192/DELNP/2014		

BIC Patents

(1007) TITLE: POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
---------	--------	-----------------	-------------	------------	------------

African Intellectual Property Organization (OAPI)	Pending	1201500240	12/19/2013		
African Regional Industrial Property Organization	Pending	AP/P/2015/008510	12/19/2013		
Anguilla	Pending	AI/A/2016/00180	12/19/2013		
Bahamas	Pending	2551	12/19/2013		
Bolivia	Published	SP-00412-2013	12/20/2013		
China	Published	201380073134.X	12/19/2013		
Congo, Democratic Republic of	Pending		12/19/2013		
Ecuador	Published	IEPI-2015-31224	12/19/2013		
El Salvador	Published	E-5002-2015	12/19/2013		
Ethiopia	Pending	ET/PI/16/204	12/19/2013		
Eurasian Patent Organization	Published	201591027	12/19/2013		
Fiji	Published	1229	12/19/2013		
Grenada	Granted		12/19/2013		7/19/2016
Guyana	Pending	1656	12/19/2013		
Haiti	Pending		12/19/2013		
India	Pending	5535/DELNP/2015	12/19/2013		
Indonesia	Allowed	P00201503852	12/19/2013		
Indonesia	Pending	P00201607128	12/19/2013		
Jamaica	Pending	18/1/5740	12/19/2013		
Kiribati	Granted		12/19/2013		9/20/2016
Moldova	Pending	a20150064	12/19/2013		
Montserrat	Granted		12/19/2013	4 OF 2016	5/27/2016
Nepal	Pending	4	12/19/2013		
Pakistan	Pending	908/2013	12/20/2013		
Philippines	Published	1-2015-501445	12/19/2013		
Philippines	Pending	1-2016-500389	12/19/2013		
Seychelles	Pending	2822954	12/19/2013		
Sierra Leone	Pending		12/19/2013		
Solomon Islands	Granted		12/19/2013	J37/379	8/5/2016
South Africa	Pending	2015/04914	12/19/2013		
South Africa	Pending	2015/07997	12/19/2013		
South Korea	Pending	10-2015-7019194	12/19/2013		
Thailand	Pending	1501003563	12/19/2013		
Turks and Caicos Islands	Granted	10226	12/19/2013	10226	9/7/2016
Tuvalu	Granted	TVP2822954	12/19/2013	TVP2822954	8/15/2016
Vietnam	Granted	1-2015-02321	12/19/2013	15503	5/16/2016

Vietnam	Pending	1-2015-04199	12/19/2013		
Virgin Islands (British)	Granted	EP2822954	12/19/2013	427/5/2016	9/21/2016

(1091) Title: SODIUM (2R,5S,13AR)-7,9-DIOXO-10-((2,4,6-TRIFLUOROBENZYL)CARBAMOYL)-2,3,4,5,7,9,13,13A-OCTAHYDRO-2,5-METHANOPYRIDO[1',2':4,5]PYRAZINO[2,1-B]OXAZEPIN-8-OLATE

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
African Regional Industrial Property Organization	Pending	AP/P/2016/009591	6/19/2015		
African Intellectual Property Organization (OAPI)	Pending	1201600454	6/19/2015		
Bolivia	Published	SP 126-2015	6/19/2015		
Bahamas	Allowed	2701	6/18/2015		
China	Published	201580033152.40	6/19/2015		
Cuba	Pending	2016-0187	6/19/2015		
Dominican Republic	Published	P2016-0327	6/19/2015		
Eurasian Patent Organization	Pending	201692414	6/19/2015		
Ecuador	Published	IEPI-2016-95566	6/19/2015		
El Salvador	Pending	2016005339	6/19/2015		
Guatemala	Pending	A2016-000262	6/19/2015		
Indonesia	Unfiled				
India	Pending	201617042937.00	6/19/2015		
Nigeria	Pending	NG/PT/C/2016/2106	6/19/2015		
Philippines	Pending				
Pakistan	Pending	382/2015	6/18/2015		
Thailand	Pending				
Trinidad and Tobago	Pending	TT/A/2016/00132	6/19/2015		
Vietnam	Pending				
South Africa	Pending	2016/08744	6/19/2015		

(1147) Title: THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Bangladesh	Pending	272/2016	11/2/2016		
Bolivia	Pending	SP-0260-2016	11/9/2016		
Bahamas	Pending		11/8/2016		
Pakistan	Pending	696/2016	11/9/2016		

Patent Cooperation Treaty	Entered NP	US2016/060989	11/8/2016
----------------------------------	------------	---------------	-----------

(1062) Title: SYNTHESIS OF POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Bahamas	Allowed	2702	6/18/2015		
China	Pending	201580033052.10	6/16/2015		
Eurasian Patent Organization	Pending	201692412	6/16/2015		
India	Pending	201717000457.00	6/16/2015		
Patent Cooperation Treaty	Entered NP	US2015/036017	6/16/2015		

TDF-Quad Patents

(221) Title:NUCLEOTIDE ANALOGS

Country	Status	Filing Date	Application No.	Patent No.	Issue Date
China (People's Republic)	Granted	7/25/1997	200810083233.70	200810083233.70	12/12/2012
China (People's Republic)	Granted	7/25/1997	97197460.8	ZL97197460.8	4/30/2008
India	Pending	7/25/1997	2076/DEL/1997		

(230) Title: NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD

Country	Status	Filing Date	Application No.	Patent No.	Issue Date
China (People's Republic)	Granted	7/23/1998	200510099916.80	ZL200510099916.8	9/24/2008
China (People's Republic)	Granted	7/23/1998	200410046290X	200410046290X	4/19/2006
India	Pending	7/24/1998	896/DEL/2002		
India	Pending	7/24/1998	963/DEL/2002		
India	Pending	7/24/1998	1362/DEL/2004		
India	Granted	7/24/1998	2174/DEL/1998	190780	3/15/2004
Indonesia	Granted	7/23/1998	W-991548	7658	4/11/2002

(692) Title: DIAMINOALKANE COMPOUNDS (VARIANTS) AND A METHOD OF PREPARING THEREOF (VARIANTS), A PHARMACEUTICAL COMPOSITION AND A THERAPEUTIC AGENT FOR INHIBITING CYTOCHROME-P450-MONOOXYGENASE, METHODS FOR TREATING AN HIV INFECTION AND VIRAL HEPATITS C, A METHOD OF MOD

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
African Intellectual Property Organization (OAPI)	Granted	1200800450	9/30/2009	14409	
African Regional Industrial Property Organization	Granted	AP/P/2008/004720	9/30/2014	AP2985	
Anguilla	Granted	AI/A/2015/00172	11/2/2015	AI/A/2015/00172	
Armenia	Granted	200900155	11/28/2014	20489	
China (People's Republic)	Granted	200780025607.30	5/29/2013	ZL200780025607.3	
China (People's Republic)	Granted	201310141408.60	4/29/2015	ZL201310141408.6	
Congo, Democratic Republic of	Pending	NP/004/EXT/2016			
Ethiopia	Granted	ET/PI/15/185	5/25/2016	134	
Eurasian Patent Organization	Allowed	201270738			
Eurasian Patent Organization	Granted	200900155	11/28/2014	20489	
Fiji	Published	1217			
Guyana	Published	1642			
Haiti	Pending				
India	Pending	10487/DELNP/2008			
Indonesia	Granted	W00200900061	8/12/2016	IDP00042227	
Jamaica	Pending	18/1/5696			
Kazakhstan	Unfiled				
Kazakhstan	Granted	200900155	11/28/2014	20489	
Kiribati	Granted	13/15	10/7/2015	13/15	
Kyrgyz Republic	Granted	200900155	11/28/2014	20489	
Moldova	Granted	200900155	11/28/2014	20489	
Montserrat	Granted		9/23/2015	3 of 2015	
Nauru	Pending				
Nepal	Pending	894			
Seychelles	Granted	2049506	5/25/2016	2049506	
Sierra Leone	Pending	EP2049506			
Solomon Islands	Granted	J37/370	2/10/2016	J37/370	
South Africa	Pending	2008/10399			
Tajikistan	Granted	200900155	11/28/2014	20489	
Thailand	Published	701003404			

Turkmenistan	Granted	200900155	11/28/2014	20489
Turks and Caicos Islands	Pending	10214		
Tuvalu	Granted		11/7/2015	TVP2049506
Vietnam	Pending	1-2009-00240		
Vietnam	Pending	1-2012-02702		
Virgin Islands (British)	Granted	415/6/2015	12/1/2015	415/6/2015

(719) Title: MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Granted	1200900273	6/30/2010	14749
African Regional Industrial Property Organization	Granted	AP/P/2009/004964	9/16/2014	AP2986
African Regional Industrial Property Organization	Granted	AP/P/2013/007042	11/30/2016	AP3915
Armenia	Granted	200901155	7/30/2014	19893
China (People's Republic)	Granted	201310326757.50	6/10/2015	10326757
China (People's Republic)	Granted	200880013255.40	8/28/2013	ZL200880013255.4
Eurasian Patent Organization	Granted	200901155	7/30/2014	19893
Fiji	Granted			
Indonesia	Granted	W00200902299	3/18/2015	IDP000038076
Kazakhstan	Granted	200901155	7/30/2014	19893
Kyrgyz Republic	Granted	200901155	7/30/2014	19893
Moldova	Granted	200901155	7/30/2014	19893
South Africa	Pending	2009/05882		
South Africa	Unfiled			
Tajikistan	Granted	200901155	7/30/2014	19893
Thailand	Pending	801000867		
Turkmenistan	Granted	200901155	7/30/2014	19893
Vietnam	Pending	1-2009-01990		
Vietnam	Pending	1-2012-02696		

(757) Title: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Granted	1201000364	9/28/2012	15589

African Regional Industrial Property Organization	Granted	AP/P/2010/005429	1/30/2015	3209
Armenia	Granted	201071173	3/31/2016	22950
Belarus	Granted	201071173	3/31/2016	22950
China (People's Republic)	Published	201510408376.00		
China (People's Republic)	Published	201310447258.10		
Ecuador	Pending	SP-10-10636		
Eurasian Patent Organization	Published	201591353		
Eurasian Patent Organization	Granted	201071173	3/31/2016	22950
India	Pending	7565/DELNP/2010		
Indonesia	Published	W00201004105		
Kazakhstan	Granted	201071173	3/31/2016	22950
Kyrgyz Republic	Granted	201071173	3/31/2016	22950
Moldova	Granted	201071173	3/31/2016	22950
South Africa	Granted	2010/08007	10/26/2011	2010/08007
Tajikistan	Granted	201071173	3/31/2016	22950
Turkmenistan	Granted	201071173	3/31/2016	22950
Vietnam	Pending	1-2010-02929		

(775) Title: METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Granted	1201100311.00	4/1/2010	15801
Bolivia	Abandoned	11-114.749	4/1/2010	
China	Granted	201080014307.70	4/1/2010	ZL201080014307.7
China	Published	201510160505.90	4/1/2010	
Eurasian Patent Organization	Granted	201190179.00	4/1/2010	22739
Eurasian Patent Organization	Published	201590979.00	4/1/2010	
Ecuador	Pending	SP-11-11391	4/1/2010	
Indonesia	Granted	W00201103554	4/1/2010	IDP000041448
India	Pending	7323/DELNP/2011	4/1/2010	
Pakistan	Pending	262/2010	3/31/2010	
Thailand	Published	1101002473.00	4/1/2010	
Vietnam	Pending	1-2011-02324	4/1/2010	
South Africa	Granted	2011/07430	4/1/2010	2011/07430

(895) Title: METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS

Country	Status	Application No.	Filing Date	Patent No.
China	Abandoned	201380007712.X		
India	Abandoned	6192/DELNP/2014		

(EMU-108) Title: Antiviral Activity and Resolution of 2-Hydroxymethyl-5-(5-Fluorocytosin-1-yl)-1,3-Oxathiolane

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Philippines	Granted	1-1992-43955	2/20/92	1-1992-43955	2/20/09
Philippines	Granted	55191	12/27/96	1-1996-55191	3/9/07
Philippines	Granted	55192	2/20/92	55192	12/19/08
Philippines	Granted	55193	2/20/92	55193	12/19/08
Philippines	Granted	55194	2/20/92	55194	12/19/08

(EMU-4000) Title: 1,3-Oxathiolane Nucleoside Analogues

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Botswana	Granted	BW/A/1998/00163	4/27/98	BW/P/2002/00042	5/22/03
Dominican Republic	Granted	1793970004607.00	7/10/97	370	7/10/17
Honduras	Granted	PICA97118	8/18/97	3775	4/25/00
Jamaica	Granted	697267	7/8/97	3615	5/25/05
Nicaragua	Granted	97.0096	12/5/97	1134RPI	5/17/99

(TRI1010) Non-Homogenous Systems for the Resolution of Enantiomeric Mixtures

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
China	Granted	99811893.1	8-Oct-99	ZL99811893.1	28-Nov-07

(TRI1020) Method of Manufacture of 1,3-Oxathiolane Nucleosides

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
China	Granted	99809992.9	12-Aug-99	ZL99809992.9	10-Mar-04

(783) Title: TABLETS FOR COMBINATION THERAPY

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Pending	1201100281		

African Regional Industrial Property Organization	Granted	AP/P/2011/05857	5/6/2015	AP3250
Armenia	Granted	201190125	5/29/2015	21313
Azerbaijan	Granted	201190125	5/29/2015	21313
Bolivia	Pending	SP-00292010		
China (People's Republic)	Granted	201080006646.00	9/11/2013	ZL201080006646.0
Ecuador	Pending	SP-11-11307		
Eurasian Patent Organization	Published	201491658		
Eurasian Patent Organization	Granted	201190125	5/29/2015	21313
India	Pending	5823/DELNP/2011		
Indonesia	Granted	W00201103098	3/30/2016	IDP000040606
Kazakhstan	Granted	201190125	5/29/2015	21313
Kyrgyz Republic	Granted	201190125	5/29/2015	21313
Moldova	Granted	201190125	5/29/2015	21313
Pakistan	Allowed	94/2010		
Singapore	Published	2014007744		
South Africa	Granted	2011/06154	5/28/2014	2011/06154
Tajikistan	Granted	201190125	5/29/2015	21313
Thailand	Published	1101001423		
Turkmenistan	Granted	201190125	5/29/2015	21313
Vietnam	Pending	1-2011-02035		

TAF-Quad Patents

(249) Title: PRODRUGS OF PHOSPHONATE NUCLEOTIDE ANALOGUES AND METHODS FOR SELECTING AND MAKING SAME

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
African Intellectual Property Organization (OAPI)	Granted	1200300003	7/20/2001	12393	12/29/2003
African Regional Industrial Property Organization	Granted	2003/002724	7/20/2001	AP 1466	9/22/2005
Anguilla	Granted	AI/A/2015/00173	7/20/2001	AI/A/2015/00173	11/2/2015
China (People's Republic)	Granted	1813161.1	7/20/2001	ZL01813161.1	12/27/2006
China (People's Republic)	Granted	200410097845.30	7/20/2001	ZL200410097845.3	7/16/2008

Congo, Democratic Republic of	Granted	NP/002/EXT/2016	7/20/2001	2016/4386	11/11/2016
Ethiopia	Granted	ET/PI/15/184	7/20/2001	135	5/25/2016
Eurasian Patent Organization	Granted	200300188	7/20/2001	4926	10/28/2004
Falkland Islands (Malvinas)	Granted		7/20/2001	15365	8/25/2015
Fiji	Published	1214	7/20/2001		
Grenada	Granted	7 of 2015	7/20/2001	7 of 2015	10/6/2015
Guyana	Published	1641	7/20/2001		
Haiti	Pending		7/20/2001		
India	Granted	9/MUMNP/2003	7/20/2001	208435	7/27/2007
India	Granted	00529/MUMNP/2006	7/20/2001	241597	7/14/2010
Indonesia	Granted	W-00200602129	7/20/2001	IDP0022897	2/20/2009
Indonesia	Granted	W-00200804005	7/20/2001	IDP000040148	2/15/2016
Indonesia	Granted	W00200300261	7/20/2001	IDP0022911	2/20/2009
Jamaica	Pending	18/1/5695	7/20/2001		
Kiribati	Granted	14/15	7/20/2001	14/15	10/7/2015
Montserrat	Granted	1961695.2	7/20/2001	1301519	9/23/2015
Nepal	Pending	669	7/20/2001		
Seychelles	Granted	1301519	7/20/2001	1301519	5/25/2016
Sierra Leone	Pending	EP1301519	7/20/2001		
Solomon Islands	Granted	J37/371	7/20/2001	J37/371	3/3/2016
South Africa	Granted	2002/10271	7/20/2001	2002/10271	12/31/2003
Turks and Caicos Islands	Pending	10213	7/20/2001		
Tuvalu	Granted		2/25/2015	TVP1301519	1/6/2016
Vietnam	Granted	1-2002-01193	7/20/2001	8475	5/24/2010
Virgin Islands (British)	Granted	414/5/2015	7/20/2001	414/5/2015	12/1/2015

(872) Title: TENOFOVIR ALAFENAMIDE HEMIFUMARATE

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
African Intellectual Property Organization (OAPI)	Granted	1201400057	8/15/2012	17070	6/29/2015
African Regional Industrial Property Organization	Granted	AP/P/2014/007437	8/15/2012	3639	3/31/2016
Bahamas	Granted	2441	8/15/2012	2441	6/19/2014
Bolivia	Pending	SP-0277-2012	8/15/2012		
China (People's Republic)	Published	201280039891.00	8/15/2012		

Ecuador	Pending	SP-14-13206-PCT	8/15/2012		
El Salvador	Pending	E-4659-2014	8/15/2012		
Eurasian Patent Organization	Published	201490208	8/15/2012		
India	Pending	1012/DELNP/2014	8/15/2012		
Indonesia	Published	P00201400805	8/15/2012		
Moldova	Pending	A20140011	8/15/2012		
Pakistan	Pending	539/2012	8/15/2012		
Philippines	Granted	1-2014-500349	8/15/2012	1-2014-500349	2/29/2016
South Africa	Allowed	2014/00582	8/15/2012		
Thailand	Pending	1401000784	8/15/2012		
Vietnam	Pending	1-2014-00440	8/15/2012		

(877) Title: METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Bahamas	Granted	2455	10/3/2012	2455	6/24/2014
Bolivia	Granted	SP-0352-2012	10/3/2012	6385-B	11/26/2014
China (People's Republic)	Published	201280048965.70	10/3/2012		
Ecuador	Published	IEPI-2014-74	10/3/2012		
El Salvador	Published	E-4696/2014	10/3/2012		
Eurasian Patent Organization	Allowed	201490753	10/3/2012		
India	Published	2953/DELNP/2014	10/3/2012		
Pakistan	Pending	671/2012	10/3/2012		

(692) Title: DIAMINOALKANE COMPOUNDS (VARIANTS) AND A METHOD OF PREPARING THEREOF (VARIANTS), A PHARMACEUTICAL COMPOSITION AND A THERAPEUTIC AGENT FOR INHIBITING CYTOCHROME-P450-MONOOXYGENASE, METHODS FOR TREATING AN HIV INFECTION AND VIRAL HEPATITS C, A METHOD OF MOD

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
African Intellectual Property Organization (OAPI)	Granted	1200800450	9/30/2009	14409	
African Regional Industrial Property Organization	Granted	AP/P/2008/004720	9/30/2014	AP2985	
Anguilla	Granted	AI/A/2015/00172	11/2/2015	AI/A/2015/00172	

Armenia	Granted	200900155	11/28/2014	20489
China (People's Republic)	Granted	200780025607.30	5/29/2013	ZL200780025607.3
China (People's Republic)	Granted	201310141408.60	4/29/2015	ZL201310141408.6
Congo, Democratic Republic of	Pending	NP/004/EXT/2016		
Ethiopia	Granted	ET/PI/15/185	5/25/2016	134
Eurasian Patent Organization	Allowed	201270738		
Eurasian Patent Organization	Granted	200900155	11/28/2014	20489
Fiji	Published	1217		
Guyana	Published	1642		
Haiti	Pending			
India	Pending	10487/DELNP/2008		
Indonesia	Granted	W00200900061	8/12/2016	IDP00042227
Jamaica	Pending	18/1/5696		
Kazakhstan	Unfiled			
Kazakhstan	Granted	200900155	11/28/2014	20489
Kiribati	Granted	13/15	10/7/2015	13/15
Kyrgyz Republic	Granted	200900155	11/28/2014	20489
Moldova	Granted	200900155	11/28/2014	20489
Montserrat	Granted		9/23/2015	3 of 2015
Nauru	Pending			
Nepal	Pending	894		
Seychelles	Granted	2049506	5/25/2016	2049506
Sierra Leone	Pending	EP2049506		
Solomon Islands	Granted	J37/370	2/10/2016	J37/370
South Africa	Pending	2008/10399		
Tajikistan	Granted	200900155	11/28/2014	20489
Thailand	Published	701003404		
Turkmenistan	Granted	200900155	11/28/2014	20489
Turks and Caicos Islands	Pending	10214		
Tuvalu	Granted		11/7/2015	TVP2049506
Vietnam	Pending	1-2009-00240		
Vietnam	Pending	1-2012-02702		
Virgin Islands (British)	Granted	415/6/2015	12/1/2015	415/6/2015

(719) Title: MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Granted	1200900273	6/30/2010	14749
African Regional Industrial Property Organization	Granted	AP/P/2009/004964	9/16/2014	AP2986
African Regional Industrial Property Organization	Granted	AP/P/2013/007042	11/30/2016	AP3915
Armenia	Granted	200901155	7/30/2014	19893
China (People's Republic)	Granted	201310326757.50	6/10/2015	10326757
China (People's Republic)	Granted	200880013255.40	8/28/2013	ZL200880013255.4
Eurasian Patent Organization	Granted	200901155	7/30/2014	19893
Fiji	Granted			
Indonesia	Granted	W00200902299	3/18/2015	IDP000038076
Kazakhstan	Granted	200901155	7/30/2014	19893
Kyrgyz Republic	Granted	200901155	7/30/2014	19893
Moldova	Granted	200901155	7/30/2014	19893
South Africa	Pending	2009/05882		
South Africa	Unfiled			
Tajikistan	Granted	200901155	7/30/2014	19893
Thailand	Pending	801000867		
Turkmenistan	Granted	200901155	7/30/2014	19893
Vietnam	Pending	1-2009-01990		
Vietnam	Pending	1-2012-02696		

(757) Title: THE USE OF SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Granted	1201000364	9/28/2012	15589
African Regional Industrial Property Organization	Granted	AP/P/2010/005429	1/30/2015	3209
Armenia	Granted	201071173	3/31/2016	22950
Belarus	Granted	201071173	3/31/2016	22950
China (People's Republic)	Published	201510408376.00		
China (People's Republic)	Published	201310447258.10		
Ecuador	Pending	SP-10-10636		
Eurasian Patent Organization	Published	201591353		
Eurasian Patent Organization	Granted	201071173	3/31/2016	22950
India	Pending	7565/DELNP/2010		
Indonesia	Published	W00201004105		

Kazakhstan	Granted	201071173	3/31/2016	22950
Kyrgyz Republic	Granted	201071173	3/31/2016	22950
Moldova	Granted	201071173	3/31/2016	22950
South Africa	Granted	2010/08007	10/26/2011	2010/08007
Tajikistan	Granted	201071173	3/31/2016	22950
Turkmenistan	Granted	201071173	3/31/2016	22950
Vietnam	Pending	1-2010-02929		

(775) Title: METHOD OF PREPARING AN INHIBITOR OF CYTOCHROME P450 MONOOXYGENASE, AND INTERMEDIATES INVOLVED

Country	Status	Application No.	Filing Date	Patent No.
African Intellectual Property Organization (OAPI)	Granted	1201100311.00	4/1/2010	15801
Bolivia	Abandoned	11-114.749	4/1/2010	
China	Granted	201080014307.70	4/1/2010	ZL201080014307.7
China	Published	201510160505.90	4/1/2010	
Eurasian Patent Organization	Granted	201190179.00	4/1/2010	22739
Eurasian Patent Organization	Published	201590979.00	4/1/2010	
Ecuador	Pending	SP-11-11391	4/1/2010	
Indonesia	Granted	W00201103554	4/1/2010	IDP000041448
India	Pending	7323/DELNP/2011	4/1/2010	
Pakistan	Pending	262/2010	3/31/2010	
Thailand	Published	1101002473.00	4/1/2010	
Vietnam	Pending	1-2011-02324	4/1/2010	
South Africa	Granted	2011/07430	4/1/2010	2011/07430

(895) Title: METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS

Country	Status	Application No.	Filing Date	Patent No.
China	Abandoned	201380007712.X		
India	Abandoned	6192/DELNP/2014		

(899) Title: THERAPEUTIC COMPOUNDS

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
China (People's Republic)	Published	201380007670.X	2/1/2013		

Eurasian Patent Organization	Published	201491287	2/1/2013
India	Pending	7100/DELNP/2014	2/1/2013

(EMU-108) Title: Antiviral Activity and Resolution of 2-Hydroxymethyl-5-(5-Fluorocytosin-1-yl)-1,3-Oxathiolane

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Philippines	Granted	1-1992-43955	2/20/92	1-1992-43955	2/20/09
Philippines	Granted	55191	12/27/96	1-1996-55191	3/9/07
Philippines	Granted	55192	2/20/92	55192	12/19/08
Philippines	Granted	55193	2/20/92	55193	12/19/08
Philippines	Granted	55194	2/20/92	55194	12/19/08

(EMU-4000) Title: 1,3-Oxathiolane Nucleoside Analogues

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Botswana	Granted	BW/A/1998/00163	4/27/98	BW/P/2002/00042	5/22/03
Dominican Republic	Granted	1793970004607.00	7/10/97	370	7/10/17
Honduras	Granted	PICA97118	8/18/97	3775	4/25/00
Jamaica	Granted	697267	7/8/97	3615	5/25/05
Nicaragua	Granted	97.0096	12/5/97	1134RPI	5/17/99

(TRI1010) Non-Homogenous Systems for the Resolution of Enantiomeric Mixtures

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
China	Granted	99811893.1	8-Oct-99	ZL99811893.1	28-Nov-07

(TRI1020) Method of Manufacture of 1,3-Oxathiolane Nucleosides

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
China	Granted	99809992.9	12-Aug-99	ZL99809992.9	10-Mar-04

For purposes of this Appendix 2, references to “PCT,” “OAPI,” “EAPO” and “ARIPO” shall not be construed or interpreted to grant rights to Licensee in any country other than those countries expressly included within the licenses granted to Licensee in Sections 2.2 and 2.3 of this Agreement.

APPENDIX 3
Emtricitabine Patents

(EMU-108) Title: Antiviral Activity and Resolution of 2-Hydroxymethyl-5-(5-Fluorocytosin-1-yl)-1,3-Oxathiolane

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Philippines	Granted	1-1992-43955	2/20/92	1-1992-43955	2/20/09
Philippines	Granted	55191	12/27/96	1-1996-55191	3/9/07
Philippines	Granted	55192	2/20/92	55192	12/19/08
Philippines	Granted	55193	2/20/92	55193	12/19/08
Philippines	Granted	55194	2/20/92	55194	12/19/08

(EMU-4000) Title: 1,3-Oxathiolane Nucleoside Analogues

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
Botswana	Granted	BW/A/1998/00163	4/27/98	BW/P/2002/00042	5/22/03
Dominican Republic	Granted	1793970004607.00	7/10/97	370	7/10/17
Honduras	Granted	PICA97118	8/18/97	3775	4/25/00
Jamaica	Granted	697267	7/8/97	3615	5/25/05
Nicaragua	Granted	97.0096	12/5/97	1134RPI	5/17/99

(TRI1010) Non-Homogenous Systems for the Resolution of Enantiomeric Mixtures

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
China	Granted	99811893.1	8-Oct-99	ZL99811893.1	11/28/07

(TRI1020) Method of Manufacture of 1,3-Oxathiolane Nucleosides

Country	Status	Application No.	Filing Date	Patent No.	Issue Date
China	Granted	99809992.9	12-Aug-99	ZL99809992.9	3/10/04

(270) Title: COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY

Country	Status	Filing Date	Application No.	Patent No.	Issue Date
Armenia	Granted	1/13/2004	200501134	15145	6/13/2011
China (People's Republic)	Published	1/13/2004	201510697340.90		
China (People's Republic)	Granted	1/13/2004	201210094391.90	ZL201210094391.9	2/24/2016
China (People's Republic)	Granted	1/13/2004	200480002190.50	200480002190.50	6/6/2012
Eurasian Patent Organization	Published	1/13/2004	201100293		

Eurasian Patent Organization	Granted	1/13/2004	200501134	15145	6/13/2011
Kazakhstan	Granted	1/13/2004	200501134	15145	6/13/2011
Kazakhstan	Pending		200501134 (PTE Application)		
Kyrgyz Republic	Granted	1/13/2004	200501134	15145	6/13/2011
Kyrgyz Republic	Granted		200501134 (PTE Application)	15145	5/31/2012
Moldova	Granted	1/13/2004	200501134	15145	6/13/2011
Tajikistan	Granted	1/13/2004	200501134	15145	6/13/2011
Turkmenistan	Granted	1/13/2004	200501134	15145	6/13/2011
Turkmenistan	Pending		200501134 (PTE Application)		

(677) Title: A PHARMACEUTICAL COMPOSITION, A METHOD OF PREPARING THEREOF, AND A METHOD OF TREATING VIRAL DISEASES USING SAID COMPOSITION

Country	Status	Filing Date	Application No.	Patent No.	Issue Date
Armenia	Granted	6/13/2006	200800033	17764	3/29/2013
China (People's Republic)	Granted	6/13/2006	200680026866.30	200680026866.30	3/27/2013
Eurasian Patent Organization	Published	6/13/2006	201201265		
Eurasian Patent Organization	Granted	6/13/2006	200800033	17764	3/29/2013
India	Pending	6/13/2006	9661/DELNP/2007		
Kazakhstan	Granted	6/13/2006	200800033	17764	3/29/2013
Kyrgyz Republic	Granted	6/13/2006	200800033	17764	3/29/2013
Moldova	Granted	6/13/2006	200800033	17764	3/29/2013
South Africa	Granted	6/13/2006	2008/00297	2008/00297	4/28/2010
Tajikistan	Granted	6/13/2006	200800033	17764	3/29/2013
Turkmenistan	Granted	6/13/2006	200800033	17764	3/29/2013

APPENDIX 4

Countries in the COBI Territory

1. Afghanistan
2. Angola
3. Anguilla
4. Antigua and Barbuda
5. Armenia
6. Aruba
7. Bahamas
8. Bangladesh
9. Barbados
10. Belarus
11. Belize
12. Benin
13. Bhutan
14. Bolivia
15. Botswana
16. British Virgin Islands
17. Burkina Faso
18. Burundi
19. Cambodia
20. Cameroon
21. Cape Verde
22. Central African Republic
23. Chad
24. Comoros
25. Congo, Rep
26. Congo, Dem. Rep. of the
27. Côte d'Ivoire
28. Cuba
29. Djibouti
30. Dominica
31. Dominican Republic
32. Ecuador
33. El Salvador
34. Equatorial Guinea
35. Eritrea
36. Ethiopia
37. Fiji Islands
38. Gabon
39. Gambia
40. Georgia
41. Ghana
42. Grenada
43. Guatemala
44. Guinea
45. Guinea-Bissau
46. Guyana
47. Haiti
48. Honduras
49. India
50. Indonesia
51. Jamaica
52. Kazakhstan
53. Kenya
54. Kiribati
55. Kyrgyzstan
56. Lao, People's Dem. Rep.
57. Lesotho
58. Liberia
59. Madagascar
60. Malawi
61. Malaysia
62. Maldives
63. Mali
64. Mauritania
65. Mauritius
66. Moldova, Rep. of
67. Mongolia
68. Montserrat
69. Mozambique
70. Myanmar
71. Namibia
72. Nauru
73. Nepal
74. Nicaragua
75. Niger
76. Nigeria
77. Pakistan
78. Palau
79. Papua New Guinea
80. Philippines
81. Rwanda
82. Saint Kitts and Nevis
83. Saint Lucia
84. Saint Vincent & the
Grenadines
85. Samoa
86. São Tomé and Príncipe
87. Senegal
88. Seychelles
89. Sierra Leone
90. Solomon Islands
91. Somalia
92. South Africa
93. South Sudan
94. Sri Lanka
95. Sudan
96. Surinam
97. Swaziland
98. Syrian Arab Republic
99. Tajikistan
100. Tanzania, U. Rep. of
101. Thailand
102. Timor-Leste
103. Togo
104. Tonga
105. Trinidad and Tobago
106. Turkmenistan
107. Turks and Caicos
108. Tuvalu
109. Uganda
110. Ukraine
111. Uzbekistan
112. Vanuatu
113. Vietnam
114. Yemen
115. Zambia
116. Zimbabwe

APPENDIX 5

Countries in the EVG- Quad Territory

1. Afghanistan
2. Angola
3. Anguilla
4. Antigua and Barbuda
5. Armenia
6. Bahamas
7. Bangladesh
8. Barbados
9. Belize
10. Benin
11. Bhutan
12. Bolivia
13. Botswana
14. British Virgin Islands
15. Burkina Faso
16. Burundi
17. Cambodia
18. Cameroon
19. Cape Verde
20. Central African Republic
21. Chad
22. Comoros
23. Congo, Rep
24. Congo, Dem. Rep. of the
25. Côte d'Ivoire
26. Cuba
27. Djibouti
28. Dominica
29. Ecuador
30. El Salvador
31. Equatorial Guinea
32. Eritrea
33. Ethiopia
34. Fiji Islands, Rep. of the
35. Gabon
36. Gambia
37. Georgia
38. Ghana
39. Grenada
40. Guatemala
41. Guinea
42. Guinea-Bissau
43. Guyana
44. Haiti
45. Honduras
46. India
47. Indonesia
48. Jamaica
49. Kazakhstan
50. Kenya
51. Kiribati
52. Kyrgyzstan
53. Lao People's Dem. Rep.
54. Lesotho
55. Liberia
56. Madagascar
57. Malawi
58. Maldives
59. Mali
60. Mauritania
61. Mauritius
62. Moldova, Rep. of
63. Mongolia
64. Mozambique
65. Myanmar
66. Namibia
67. Nauru
68. Nepal
69. Nicaragua
70. Niger
71. Nigeria
72. Pakistan
73. Palau
74. Papua New Guinea
75. Rwanda
76. Saint Kitts and Nevis
77. Saint Lucia
78. Saint Vincent & the Grenadines
79. Samoa
80. São Tomé and Príncipe
81. Senegal
82. Seychelles
83. Sierra Leone
84. Solomon Islands
85. Somalia
86. South Africa
87. South Sudan
88. Sri Lanka
89. Sudan
90. Suriname
91. Swaziland
92. Syrian Arab Republic
93. Tajikistan
94. Tanzania, U. Rep. of
95. Thailand
96. Timor-Leste
97. Togo
98. Tonga
99. Trinidad and Tobago
100. Turkmenistan
101. Turks and Caicos
102. Tuvalu
103. Uganda
104. Uzbekistan
105. Vanuatu
106. Vietnam
107. Yemen
108. Zambia
109. Zimbabwe

APPENDIX 6

Countries in the BIC Territory

1. Afghanistan
2. Angola
3. Anguilla
4. Antigua and Barbuda
5. Armenia
6. Aruba
7. Bahamas
8. Bangladesh
9. Barbados
10. Belarus
11. Belize
12. Benin
13. Bhutan
14. Bolivia
15. Botswana
16. British Virgin Islands
17. Burkina Faso
18. Burundi
19. Cambodia
20. Cameroon
21. Cape Verde
22. Central African Republic
23. Chad
24. Comoros
25. Congo, Rep
26. Congo, Dem. Rep. of the
27. Côte d'Ivoire
28. Cuba
29. Djibouti
30. Dominica
31. Dominican Republic
32. Ecuador
33. El Salvador
34. Equatorial Guinea
35. Eritrea
36. Ethiopia
37. Fiji Islands
38. Gabon
39. Gambia
40. Georgia
41. Ghana
42. Grenada
43. Guatemala
44. Guinea
45. Guinea-Bissau
46. Guyana
47. Haiti
48. Honduras
49. India
50. Indonesia
51. Jamaica
52. Kazakhstan
53. Kenya
54. Kiribati
55. Kyrgyzstan
56. Lao, People's Dem. Rep.
57. Lesotho
58. Liberia
59. Madagascar
60. Malawi
61. Malaysia
62. Maldives
63. Mali
64. Mauritania
65. Mauritius
66. Moldova, Rep. of
67. Mongolia
68. Montserrat
69. Mozambique
70. Myanmar
71. Namibia
72. Nauru
73. Nepal
74. Nicaragua
75. Niger
76. Nigeria
77. Pakistan
78. Palau
79. Papua New Guinea
80. Philippines
81. Rwanda
82. Saint Kitts and Nevis
83. Saint Lucia
84. Saint Vincent & the
Grenadines
85. Samoa
86. São Tomé and Príncipe
87. Senegal
88. Seychelles
89. Sierra Leone
90. Solomon Islands
91. Somalia
92. South Africa
93. South Sudan
94. Sri Lanka
95. Sudan
96. Surinam
97. Swaziland
98. Syrian Arab Republic
99. Tajikistan
100. Tanzania, U. Rep. of
101. Thailand
102. Timor-Leste
103. Togo
104. Tonga
105. Trinidad and Tobago
106. Turkmenistan
107. Turks and Caicos
108. Tuvalu
109. Uganda
110. Ukraine
111. Uzbekistan
112. Vanuatu
113. Vietnam
114. Yemen
115. Zambia
116. Zimbabwe